LNF 2007
Alternative Names: LNF-2007Latest Information Update: 07 Jan 2025
At a glance
- Originator Lunan Pharmaceutical Group
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 07 Jan 2025 Shandong New Time Pharmaceutical Co plans a phase I trial for solid tumour (Late-stage disease, Monotherapy) in January 2025 (IV, Infusion) (NCT06752447)
- 05 Apr 2024 Preclinical trials in Solid tumours in China (Parenteral) before April 2024
- 05 Apr 2024 Pharmacodynamics and adverse events data from a preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)